Review Article

About Primary Pulmonary Leiomyosarcoma: A Very Rare Highly Aggressive Neoplasm -  

Mirko Barone*, Marco Prioletta, Luigi Guetti, Giuseppe Cipollone, Decio Di Nuzzo, Pierpaolo Campilese, Felice Mucilli

Department of General and Thoracic Surgery, University Hospital “SS. Annunziata”, University “G. d’Annunzio” Chieti, Italy

*Address for Correspondence: Mirko Barone, Department of General and Thoracic Surgery, University “G. d’Annunzio”, Via dei Vestini n.1, 66100. Chieti, Italy, Tel: +390871358289; Fax: +390871358289; E-mail: mir87mb@libero.it

Submitted: 12 December 2016; Approved: 24 January 2017; Published: 27 January 2017


Copyright: © 2017 Barone M, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Primary Pulmonary Leiomyosarcoma (PPL) is an extremely rare and highly aggressive mesenchymal tumor arising from the smooth muscle cells of the bronchial or pulmonary vessel walls. It accounts for less than 0.5% of all lung cancers [1]. It can be classified as intraluminal or intrabronchial, intrapulmonary and intravascular according to its gross appearance [2]. Nath, et al. [3] recently reviewed the literature and reported 127 PPL cases. Aim of this work is a complete and exhaustive review on the morphological characteristics, clinical findings and current therapeutic strategies according to recent reports present in the literature.

MATERIALS AND METHODS

The authors conducted a comprehensive research on PubMed - Medline including a period from January 2010 to June 2016 and according to the following MeSH terms: “primary [All Fields] AND (“lung” [MeSH Term] OR “lungs” [All Fields] OR “pulmonary” [All Fields]) AND (“leiomyosarcoma” [MeSH Terms] OR “leiomyosarcoma” [All Fields])”. All case reports or case studies were enclosed, while reviews prior to 2010 were excluded and resulting in twenty-one published reports [1,4-23] including primary intrapulmonary, primary intrabronchial and primary intravascular leiomyosarcomas.

Data collection included demographic characteristics (age, gender), neoplasm’s histopathological features, therapeutic strategies and follow up.

Statistical analysis was performed using SPSS version 20.0 software for Windows (IBM, Chicago, USA). Continuous variables were expressed as absolute value, simple percentages, means and standard deviations, whereas categorical ones in terms of frequency and percentage. Statistical differences or correlations between cohorts were evaluated with two sample t-test, χ2 test and McNemar’s test. Survival variables were estimated according to the Kaplan-Meier’s method with 1-, 2- and 3-year’s rates. A p-value < 0.05 was considered statistically significant.

RESULTS

Table 1 summarizes the demographic, clinical and pathological findings of the reported cases in the literature.

Twenty-two patients with a mean age of 54.07 ± 13.34 years (range 35-80) and a male to female ratio of 1:1 were enrolled in the study. With regard to morphological appearance, vascular neoplasms (primary pulmonary artery leiomyosarcomas) were the most common (N.10–45.45%), followed by intrapulmonary and interbronchial ones (N.8 – 36.36 % and n. 4–18.18 %, respectively). This is in contrast with previous reviews published prior to 2010.

In spite of the highly aggressive biological behaviour, secondary lesions were present in PPL with clinical presentation only in 27.27% (N.6), with the lung being the most common site of recurrence, suggesting an early locoregional spread. In addition, mediastinal lymph node metastases were rare (N.4–18.18%) in accordance with the hematological tropism of sarcomatous malignancies.

A sequential multimodal therapeutic approach was the most common strategy, although cases of only surgical resections (N.5–22.72%) were described. Furthermore, in three patients, only bronchoscopic or CT-guided biopsies could be performed due to the rapid and fatal evolution of the disease itself.

Concerning risk factors affecting Overall Survival (OS), no statistical correlation was observed with age (p = 0.206), gender (p = 0.206), morphology (p = 0.669), mediastinal lymph node metastases (p = 0.210) and metastases (p = 0.291). But an important relationship between metastatic disease and mortality rate was reported (p = 0.082) (Table 2). Although it may seem a contradiction, this is justifiable referring to PPL’s high biological aggressiveness that, even in the early stages, has a poor prognosis. However, the presence of a stage IV correlates with a rapid progression affecting the overall mortality rate.

With regard to follow-up (range 0–36 months), no data were collected in five patients. In the remaining cases, a cumulative OS of 9.17 ± 3.77 (CI 95% OS: 9.71-24.49) months with a mortality rate of 58.82% (n.10/17) was observed. The 1-year OS was 53.6% (S.E. 0.133), whereas the 2- and 3-year OS was, 26.8% (S.E. 0.128) and 0%, respectively (Figure 1).

Clustering the population according to the morphological type, no significant statistical differences in survival were found (Log Rank Mantel-Cox, p = 0.754). In particular, the actuarial median OS for intravascular patients was 14.12 ± 4.15 months, for intrabronchial 12.17 ± 1.31 mo and for intrapulmonary 19.50 ± 7.13 mo (Figure 2).

In our experience, from 1998 to 2016, only a 78-years old male patient with a T3N1M0 intrapulmonary leiomyosarcoma was admitted to our Department. He underwent upper pulmonary bilobectomy with partial thoracectomy with reconstruction (Figure 3,4) and subsequent adjuvant chemoradiotherapy. Ten months after surgery, the patient was still alive but a recurrence on the residual right lung was diagnosed.

DISCUSSION

Primary Pulmonary Leiomyosarcoma (PPL) is an extremely rare and highly-aggressive mesenchymal tumor arising from the smooth muscle cells of the bronchial or pulmonary vessel walls and accounts for less than 0.5% of all lung cancers [1]. Nath, et al. [3] recently

ABBREVIATIONS

Primary Pulmonary Leiomyosarcoma (PPL); Overall Survival (OS); Chemotherapy (CHT); Radiotherapy (XRT)
Table 1: Primary pulmonary leiomyosarcoma cases published from 2010 to 2016. Demographic, clinical and therapeutic findings.

<table>
<thead>
<tr>
<th>Author</th>
<th>N. patients</th>
<th>Age</th>
<th>Gender</th>
<th>Morphology</th>
<th>Site</th>
<th>Metastases</th>
<th>Location</th>
<th>pN2</th>
<th>Treatment strategy</th>
<th>CHT protocol</th>
<th>Follow-up (months)</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vakilian F</td>
<td>1</td>
<td>35</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>Surgery + CHT</td>
<td>docetaxel + gemcitabine</td>
<td>4</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Xie X</td>
<td>1</td>
<td>48</td>
<td>M</td>
<td>intrabronchial</td>
<td>right upper lobe</td>
<td>Yes</td>
<td>Lung, Bone</td>
<td>Yes</td>
<td>CHT</td>
<td>epirubicin + ifosfamide</td>
<td>0,5</td>
<td>yes</td>
</tr>
<tr>
<td>Colwell EM</td>
<td>1</td>
<td>69</td>
<td>F</td>
<td>intrapulmonary</td>
<td>left inferior lobe</td>
<td>Yes</td>
<td>Brain</td>
<td>No</td>
<td>XRT + surgery+CHT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munganinskaya N</td>
<td>1</td>
<td>72</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary arteries</td>
<td>No</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Srividya VV</td>
<td>1</td>
<td>49</td>
<td>F</td>
<td>intravascular</td>
<td>right inferior pulmonary vein</td>
<td>No</td>
<td>No</td>
<td>Surgery</td>
<td>gemcitabine</td>
<td>10</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Shen W</td>
<td>1</td>
<td>52</td>
<td>F</td>
<td>intrapulmonary</td>
<td>right-middle lobe</td>
<td>No</td>
<td>No</td>
<td>Surgery</td>
<td>adriamycin</td>
<td>28</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Adel SH</td>
<td>1</td>
<td>64</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>Surgery + CHT</td>
<td>adriamycine</td>
<td>3</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Galeone A</td>
<td>1</td>
<td>29</td>
<td>M</td>
<td>intravascular</td>
<td>right inferior pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>Surgery + CHT+XRT</td>
<td>gemcitabine and paclitaxel</td>
<td>24</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Staller B</td>
<td>1</td>
<td>43</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kanematsu T</td>
<td>1</td>
<td>56</td>
<td>M</td>
<td>intrapulmonary</td>
<td>right lung</td>
<td>Yes</td>
<td>Lung</td>
<td>Yes</td>
<td>CHT</td>
<td>adriamycine, ifosfamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Falkenstern-Ge RF</td>
<td>1</td>
<td>70</td>
<td>M</td>
<td>intrabronchial</td>
<td>left main bronchus</td>
<td>No</td>
<td>No</td>
<td>Surgery + CHT</td>
<td></td>
<td>24</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Kashima K</td>
<td>1</td>
<td>53</td>
<td>M</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>Surgery + CHT</td>
<td>pirarubicin, cyclophosphamide</td>
<td>20</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Luthra M</td>
<td>1</td>
<td>43</td>
<td>F</td>
<td>intrapulmonary</td>
<td>right inferior lobe</td>
<td>No</td>
<td>No</td>
<td>Surgery+CHT+XRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elouazzani H</td>
<td>2</td>
<td>37,5</td>
<td>M, F</td>
<td>intrabronchial</td>
<td>right upper-middle lobe</td>
<td>No</td>
<td>Yes</td>
<td>Surgery + CHT</td>
<td></td>
<td>12</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Ma Y</td>
<td>1</td>
<td>62</td>
<td>M</td>
<td>intrapulmonary</td>
<td>left inferior lobe</td>
<td>Yes</td>
<td>Lung, Skin</td>
<td>No</td>
<td>CHT</td>
<td>ifosfamide, etoposide, cisplatin, idarubicin</td>
<td>24</td>
<td>yes</td>
</tr>
<tr>
<td>Sardenberg RA</td>
<td>1</td>
<td>44</td>
<td>M</td>
<td>intrapulmonary</td>
<td>left inferior lobe</td>
<td>No</td>
<td>No</td>
<td>Surgery</td>
<td></td>
<td>36</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Flaherty G</td>
<td>1</td>
<td>69</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>Yes</td>
<td>Kidney</td>
<td>No</td>
<td></td>
<td></td>
<td>0</td>
<td>yes</td>
</tr>
<tr>
<td>Colak N</td>
<td>1</td>
<td>58</td>
<td>F</td>
<td>intravascular</td>
<td>main pulmonary trunk</td>
<td>No</td>
<td>No</td>
<td>surgery</td>
<td></td>
<td>8</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>Rozada R</td>
<td>1</td>
<td>60</td>
<td>M</td>
<td>intrapulmonary</td>
<td>left inferior lobe</td>
<td>Yes</td>
<td>Lung, Bone</td>
<td>Yes</td>
<td></td>
<td></td>
<td>0</td>
<td>yes</td>
</tr>
<tr>
<td>Kosaka M</td>
<td>1</td>
<td>80</td>
<td>M</td>
<td>intrapulmonary</td>
<td>left inferior lobe</td>
<td>No</td>
<td>No</td>
<td>chemotherapy</td>
<td></td>
<td>1,5</td>
<td>yes</td>
<td></td>
</tr>
</tbody>
</table>

M: male; F: female; CHT: chemotherapy; XRT: radiotherapy; pN2: intrathoracic N2 (mediastinal) lymph node metastases.

reviewed the literature and reported 127 PPL cases. It can be classified as intraluminal or intrabronchial, intrapulmonary and intravascular according to its gross appearance [2]. The intrapulmonary type is the most common, while the intravascular one arises from pulmonary vessel intimae causing obstructions, stenoses or recurrent pulmonary embolisms [24]. Moreover, this latter is a very rare and highly aggressive neoplasm [25] with an incidence of 0.001-0.3% [26].

PPLs usually appear as a solitary pulmonary mass in middle-aged patients. Intravascular forms can engage the right ventricle outflow tract, the main pulmonary trunk or one of the pulmonary branches with an earlier onset and women are doubly affected than men [27].

The underlying pathophysiology and the promoting genetic mechanisms of these tumors are still unclear. However, recognized risk factors include radiation therapy, chemotherapy (e.g. cyclophosphamide, nitrosoureas), and environmental and occupational exposures [28]. Patients may present with nonspecific signs and symptoms similar to those observed in other lung cancers, including fever, cough, hemoptysis, dyspnea and chest pain [29], although the constellation of symptoms can vary according to the neoplastic morphological pattern. In particular, in the case of endobronchial lesions, patients may complain of obstructive respiratory symptoms [30], on the other hand, in the case of vascular tumors, signs and symptoms of hemodynamic mismatch associated with respiratory failure are predominant, frequently leading to misdiagnosed cases of pulmonary thromboembolism [31,32].

It is difficult to distinguish PPLs from other lung cancers, pulmonary tuberculosis, granulomatosis and mediastinal tumors [33]. Physical examination, ECG usually does not reveal abnormalities and chest X-ray is often aspecific. For these reasons imaging must be completed by chest CT. Masses obstructing the
Table 2: Bivariate analysis between independent factors and survival.

<table>
<thead>
<tr>
<th>Factor</th>
<th>OS</th>
<th>Mortality rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agea</td>
<td>0.200</td>
<td>0.354</td>
</tr>
<tr>
<td>Gender (male vs female)b</td>
<td>0.206</td>
<td>0.458</td>
</tr>
<tr>
<td>Morphology (intravascular vs intrabronchial vs intrapulmonary)b</td>
<td>0.669</td>
<td>0.919</td>
</tr>
<tr>
<td>Metastases (Yes vs No)b</td>
<td>0.291</td>
<td>0.082</td>
</tr>
<tr>
<td>pN22 (Yes vs No)b</td>
<td>0.210</td>
<td>0.156</td>
</tr>
</tbody>
</table>

*acontinuous variable; *categorical variable

Overall Survival; p-pathological mediastinal (N2) lymph nodes

Statistical significance: \( p < 0.05 \)

Figure 1: General population (N. 17) cumulative overall survival according to Kaplan and Meier’s method.

Figure 2: Patients cohorts according to tumor’s gross appearance vs overall survival (Kaplan and Meier’s method).
main pulmonary vessels can be associated with both cardiomegaly and radiological signs of peripheral hypoperfusion [34]. Radio graphically, PPL appears as a well-defined mass with heterogeneous density, small calcifications or diffuse ischemic areas. It is generally a hilar neoplasm, but peripheral tumors with or without chest wall involvement has been described. Moreover, radiological appearances can also include findings such as obstructive atelectasis, mediastinal shift or pneumothorax [30]. On the other hand, in presence of a suspected intravascular type, a wall eclipsing sign on a pulmonary CT angiogram is suggestive of pathogenicity [35]. While ventilation/perfusion scans make difficult to differentiate it between intravascular lesions and pulmonary embolism, a fluorine-18 fluorodeoxyglucose positron emission tomography scan has shown radiopharmaceutical uptake only by malignant tumors [36]. Moreover, magnetic resonance imaging could also differentiate a mass from a thrombus based on signal homogeneity [37].

Finally, Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) should be considered as an effective tool to diagnose intrabronchial neoplasms in selected cases [38].

The definitive diagnosis is mainly histological. Macroscopically, PPL presents with a roughly pearly surface; whereas, microscopically, the majority of these tumors presents a fascicular proliferation of spindle cells with a moderate amount of eosinophilic cytoplasm and inconspicuous nucleoli. Pulmonary leiomyosarcoma can show a broad spectrum of differentiation. Low grade FNCLCC stage I (French Federation Nationale des Centres de LutteContre le Cancer) tumors are characterized by fascicular arrangement, low mitotic rate (<3 per 10 HPF), the absence of cellular atypia, necrosis or hemorrhage and by a negative reaction to cytokeratin and epithelial markers (AE1/AE3, KL1, CK7, CK20, CK5/6). Ki-67 is less than 5%. Intermediate grade tumors are characterized by an increased cellularity with mild to moderate nuclear atypia and a mild mitotic activity (3-8 mitoses per 10 HPF). Finally, high-grade tumors show a marked cellularity with nuclear pleomorphism and atypia, high mitotic activity (>8 mitoses per 10 HPF) and abundant areas of hemorrhage and necrosis [39]. Immunohistochemical positivity to actin, SMA, h-caldesmone and desmin can assume a smooth muscle neoplasm origin. Negativity to CD99, EMA and S100 allows you to exclude neoplasms such as Ewing’s sarcoma, undifferentiated tumors of epithelial origin and tumors of the nervous tissue [40]. Early stage pulmonary leiomyosarcomas are amenable for surgical resection (lobectomy, pneumonectomy, sleeve lobectomies, carinal resections with reconstruction according to Grillo or Brochart and endarterectomies) [41], which has to be considered the treatment of choice [42]. As reported by Tanaka, et al. [43], in a fascinating earlier review on 47 patients with primary pulmonary artery sarcoma, local recurrence after surgery significantly affects overall survival. For these reason the author proposed wider and careful tumor isolation with reconstruction with prostheses or grafts. Lymph node resections are generally not necessary because primary leiomyosarcomas rarely show lymph node involvement. If a radical resection is performed, the 5-years survival rate can achieve 50% for initial stage diseases, but long-survival case have been reported [12,22,35].

Prognostic factors include tumor’s dimension, bronchial and thoracic wall invasion. In addition, tumor cell necrosis, high cellularity, mitotic count above four and nuclear atypia are all predictive of more aggressive behavior and therefore increased risk of recurrence [44].

The role of adjuvant treatments is still debated; radio chemotherapy is recommended in cases of incomplete resection (R1 or R2) or recurrences [45], but the limited experiences in the treatment of these tumors makes it difficult to assess the relative importance of surgical resection and of adjuvant strategies, though Head HD et al are in favor of adjuvant protocols with encouraging results [46]. However, the therapeutic efficacy is controversial. In the majority of reports, adjuvant therapies have been largely ineffective making them to be considered unsensitive neoplasms. Sardenberg, et al. [47] reported a classic fractioning 50-60 Gy radiation protocol with good local field control.

With regard to conventional or intensive chemotherapy, standard-dose ifosfamide, doxorubicin and high-dose ifosfamide have been described. Trabectedin and dacarbazine as 2nd-line options have proved effectiveness in leiomyosarcoma [48]. However, response rates are usually less than 20%. On the other hand, adriamycin-based protocols have achieved response rate in only 16-27% [49].

CONCLUSION

In conclusion, PPL is a rare malignancy, difficult to differentiate from other lung cancers. Characterized by high biological aggressiveness and high resistance to conventional therapies, early detection and surgical therapy in selected cases can improve its poor and dismal prognosis. A better molecular characterization would definitely be crucial. Furthermore, the creation of multicentre and international databases in order to gather more experience and develop appropriate guidelines would be beneficial.

REFERENCES


